The global In Vitro Diagnostics (IVD) Quality Control Market is projected to grow from USD 1.65 billion in 2025 to USD 2.15 billion by 2030, registering a CAGR of 5.5% during the forecast period. Market growth is being driven by the increasing number of accredited laboratories and the rising demand for external quality assessment (EQA) programs to ensure diagnostic accuracy and compliance.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582
Market Dynamics: Accreditation and Quality Assurance Drive Adoption
The growing emphasis on laboratory accreditation from global regulatory bodies such as International Organization for Standardization, College of American Pathologists, and Clinical Laboratory Improvement Amendments is significantly boosting demand for robust IVD quality control solutions.
Laboratories are increasingly adopting advanced QC products and participating in EQA programs to ensure testing accuracy, reproducibility, and compliance. This shift is reinforcing the importance of independent quality assessment tools and driving sustained market expansion.
Segment Insights: Third-Party Controls Dominate the Market
By manufacturer type, third-party controls accounted for the largest share of the IVD quality controls market in 2024. Their widespread adoption is attributed to their compatibility across multiple instruments and reagent systems, offering laboratories greater flexibility and cost efficiency.
Unlike OEM controls, third-party solutions provide an independent and unbiased assessment of laboratory performance. Their longer shelf life, stable analyte composition, and clinically relevant ranges make them a preferred choice for laboratories seeking standardization and regulatory compliance.
End-User Trends: Clinical Laboratories to Witness Fastest Growth
By end user, clinical laboratories are expected to register the fastest growth during the forecast period. The increasing volume of diagnostic testing, particularly in specialized and independent labs, is driving demand for high-quality QC solutions.
These laboratories are prioritizing accuracy, reproducibility, and workflow efficiency—leading to increased adoption of multianalyte controls, automated QC systems, and data management solutions. The expansion of high-throughput testing further supports the need for scalable and reliable quality control systems.
Regional Outlook: North America Leads Global Market
North America holds the largest share of the IVD quality controls market, supported by advanced healthcare infrastructure, strong regulatory oversight, and high diagnostic testing volumes.
The region’s leadership is further reinforced by early adoption of automated and molecular diagnostic technologies, as well as a strong presence of leading industry players. Continuous investments in innovation and stringent quality standards ensure sustained demand for advanced QC solutions.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=198032582
Competitive Landscape: Focus on Innovation and Compliance
The IVD quality controls market is highly competitive, with leading players focusing on expanding product portfolios, enhancing QC accuracy, and supporting regulatory compliance. Key companies include: Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK), LGC Limited (UK), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), Danaher Corporation (US), Sysmex Corporation (Japan), Bio-Techne Corporation (US), Microbix Biosystems Inc. (Canada), Microbiologics, Inc. (US), ZeptoMetrix (US), Fortress Diagnostics (UK), Helena Laboratories Corporation (US), Streck, Inc. (US), SERO AS (Norway), Maine Molecular Quality Controls, Inc. (US), Sun Diagnostics, LLC (US), Alpha-Tec (US), Grifols, S.A. (Spain), ConeBioproducts (US), Eurotrol B.V. (Netherlands), and Biorex Diagnostics (UK).
These companies are investing in advanced QC materials, digital quality management systems, and global distribution capabilities to meet the evolving needs of diagnostic laboratories.
Strategic Outlook: Quality Control as a Cornerstone of Diagnostic Excellence
As diagnostic testing becomes more complex and high-throughput, quality control is emerging as a critical pillar of laboratory operations. The shift toward automation, molecular diagnostics, and point-of-care testing is further increasing the need for reliable and scalable QC solutions.
Going forward, innovation in multianalyte controls, data integration, and real-time monitoring will shape the future of the market—ensuring improved diagnostic accuracy, regulatory compliance, and patient outcomes.
